How to Develop Strong Evidence to Enable Optimal Access Recording

Home / Intelligence / Webinars / How to Develop Strong Evidence to Enable Optimal Access Recording

Available On Demand

Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.

  • But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
  • What are the ‘nuts and bolts’ of designing and conducting such studies?
  • How do you distill down to the key value messages from a complex data set to be most impactful to clinical and payer audiences?

Learn how Burden of Illness studies are conducted and how this study type could support your disease areas! The Trinity team will highlight the importance of evidence generation through the lens of a scientific Burden of Illness study that we recently conducted with a global pharma company. Beyond the scientific implications of studies of this kind, we will delve into the real-world applications of this evidence from a market access perspective.

Please complete the form to watch our Trinity Webinar: How to Develop Strong Evidence to Enable Optimal Access.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.

Related Intelligence

Webinars

Part D in Peril: The Inconvenient Math of IRA Part D Redesign 

August 14, 2025 | 12:00 – 12:45 PM ET

Medicare Part D is undergoing its most significant transformation in decades largely driven by the IRA. What does this mean for pharmaceutical manufacturers? Join us for an engaging discussion with Max Hunt, Partner at Trinity, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage.

 Sign Up Now

Blog

Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know

March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]

 Read More

Blog

Pricing and Access in Germany: Innovation and Strong Evidence Rewarded

Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]

 Read More